Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
LncRNA VINAS regulates atherosclerosis by modulating NF-κB and MAPK signaling
Viorel Simion, … , Peter Libby, Mark W. Feinberg
Viorel Simion, … , Peter Libby, Mark W. Feinberg
Published October 6, 2020
Citation Information: JCI Insight. 2020;5(21):e140627. https://doi.org/10.1172/jci.insight.140627.
View: Text | PDF
Research Article Vascular biology

LncRNA VINAS regulates atherosclerosis by modulating NF-κB and MAPK signaling

  • Text
  • PDF
Abstract

Long noncoding RNAs (lncRNAs) play important roles in regulating diverse cellular processes in the vessel wall, including atherosclerosis. RNA-Seq profiling of intimal lesions revealed a lncRNA, VINAS (Vascular INflammation and Atherosclerosis lncRNA Sequence), that is enriched in the aortic intima and regulates vascular inflammation. Aortic intimal expression of VINAS fell with atherosclerotic progression and rose with regression. VINAS knockdown reduced atherosclerotic lesion formation by 55% in LDL receptor–deficient (LDLR–/–) mice, independent of effects on circulating lipids, by decreasing inflammation in the vessel wall. Loss- and gain-of-function studies in vitro demonstrated that VINAS serves as a critical regulator of inflammation by modulating NF-κB and MAPK signaling pathways. VINAS knockdown decreased the expression of key inflammatory markers, such as MCP-1, TNF-α, IL-1β, and COX-2, in endothelial cells (ECs), vascular smooth muscle cells, and bone marrow–derived macrophages. Moreover, VINAS silencing decreased expression of leukocyte adhesion molecules VCAM-1, E-selectin, and ICAM-1 and reduced monocyte adhesion to ECs. DEP domain containing 4 (DEPDC4), an evolutionary conserved human ortholog of VINAS with approximately 74% homology, showed similar regulation in human and pig atherosclerotic specimens. DEPDC4 knockdown replicated antiinflammatory effects of VINAS in human ECs. These findings reveal a potentially novel lncRNA that regulates vascular inflammation, with broad implications for vascular diseases.

Authors

Viorel Simion, Haoyang Zhou, Jacob B. Pierce, Dafeng Yang, Stefan Haemmig, Yevgenia Tesmenitsky, Galina Sukhova, Peter H. Stone, Peter Libby, Mark W. Feinberg

×

Figure 5

In vivo knockdown of VINAS inhibits atherosclerotic lesion formation by decreasing vascular inflammation.

Options: View larger image (or click on image) Download as PowerPoint
In vivo knockdown of VINAS inhibits atherosclerotic lesion formation by ...
(A) LDLR–/– mice were i.v. injected with vehicle control gapmeR (n = 15) or VINAS gapmeR (n = 13) twice per week (10 mg/kg/mouse/injection) and placed on an HCD for 12 weeks. Representative images and quantification for Oil Red O (scale bar: 400 μm) (B), VCAM-1 (C), Mac-2 (D), CD4+ (E), CD8+ (F), and ACTA2 (G) staining (arrowhead) of the aortic sinus of LDLR–/– HCD mice treated with control (n = 15) or MAARS (n = 13) gapmeRs for 12 weeks. Scale bar: 100 μm. VINAS silencing efficiency and expression of inflammatory markers was assessed by RT-qPCR in the intima (H) and media (I) fractions of the aortic arch from control gapmeR (n = 6) and VINAS gapmeR groups (n = 5). Data represent the mean ± SD. Statistical differences were calculated using unpaired 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts